Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q2 2024 Blueprint Medicines Corp Earnings Call Transcript

Aug 01, 2024 / 12:00PM GMT
Release Date Price: $100.29 (-7.40%)
Operator

Hello, everyone. At this time, I would like to welcome everyone to the Blueprint Medicines Second Quarter 2024 financial results conference call. My name is Bruno, and I'll be operating your call today. All lines have been placed on mute to prevent any background noise. (Operator Instructions) I'll now hand over to your host Jenna Cohen, please, you may begin your conference.

Jenna Cohen
Blueprint Medicines Corp - Vice President and Head, Investor Relations

Thank you, Bruno. Good morning, everyone, and welcome to Blueprint Medicines' Second Quarter 2024 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer;Christin Rossi, Chief Operating

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot